NPCE — Neuropace Balance Sheet
0.000.00%
Last trade - 00:00- $382.65m
- $373.15m
- $65.42m
- 46
- 12
- 89
- 47
Annual balance sheet for Neuropace, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 5.09 | 38.1 | 116 | 77.4 | 66.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.02 | 8.39 | 7.09 | 7.48 | 12.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 20.3 | 54.6 | 133 | 97.7 | 92.7 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.81 | 0.515 | 0.603 | 15.9 | 14.4 |
| Other Long Term Assets | |||||
| Total Assets | 21.1 | 56 | 134 | 114 | 108 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 75.1 | 9.6 | 9.3 | 11 | 16.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 76.9 | 62.4 | 60.1 | 79.3 | 87 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -55.8 | -6.41 | 73.5 | 34.8 | 20.7 |
| Total Liabilities & Shareholders' Equity | 21.1 | 56 | 134 | 114 | 108 |
| Total Common Shares Outstanding |